SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- October 30, 2006 -- Novacea, Inc. (NASDAQ: NOVC) today announced that the on-line version of the Journal of Cancer Chemotherapy and Pharmacology (http://dx.doi.org/10.1007/s00280-006-0299-1) has published data from a Phase 1 study of the company’s lead investigational cancer therapy, Asentar™ (DN-101). The study was conducted at Oregon Health and Science University and Roswell Park Cancer Institute under the leadership of Dr. Tomasz Beer and Dr. Donald Trump. The publication, entitled “Phase 1 study of weekly DN-101, a new formulation of calcitriol, in patients with cancer,” reports that Asentar was safe and well tolerated during weekly administration. Asentar is a new, high-dose oral formulation of calcitriol, the most potent natural metabolite of vitamin D, presently being investigated in Novacea’s ASCENT-2 Phase 3 clinical study as a potential treatment for men with advanced prostate cancer.
